Labcorp enhances cell and gene therapy development support through collaboration with Xcell Biosciences

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 19, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, is collaborating with Xcell Biosciences, Inc. (Xcellbio), a leading developer of cell and gene therapy technologies, to advance critical work that helps clients effectively bring innovative cell and gene therapies to market.

Needs Beyond Medicine receives $10,000 grant from The Labcorp Charitable Foundation

SALT LAKE CITY, Utah, April 6, 2022 — Needs Beyond Medicine today announced the receipt of a $10,000 grant from The Labcorp Charitable Foundation in support of its Relief Program, which brings critical assistance to adults with cancer who are facing the fight of their lives.

Labcorp initiates quarterly dividend

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 7, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors (the Board) has declared a cash dividend of $0.72 per share of common stock. 

New Immundiagnostik test simplifies detecting, measuring unintentional gluten consumption

MANCHESTER, N.H., April 5, 2022 — Immundiagnostik, Inc., the North American subsidiary of Immundiagnostik AG, has collaborated with Labcorp (NYSE: LH), a leading global life sciences company, to help individuals detect and quantify unintentional gluten consumption by utilizing a new fecal gluten test. The quantitative test developed by Immundiagnostik and offered exclusively through Labcorp detects the presence of gluten in a patient’s stool sample and has a high sensitivity and specificity.